Sath Shukla

CIK: 0001782817

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (75.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SPRO

Spero Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

SPRO
Spero Therapeutics, Inc.
Feb 5, 2025
Sale(S)
Direct
6.1K shares at avg. $0.78$5K
SPRO
Spero Therapeutics, Inc.
Feb 5, 2025
Sale(S)
Direct
42.8K shares at avg. $0.78$33K
SPRO
Spero Therapeutics, Inc.
Feb 5, 2025
Sale(S)
Direct
106.4K shares at avg. $0.78$83K
SPRO
Spero Therapeutics, Inc.
Feb 3, 2025
Award(A)
Direct
751.4K shares-

		Type	Shares	Price		Ownership
Feb 5, 2025	SPRO Spero Therapeutics, Inc.	Sale(S)	6,139	$0.78	$4,788	Direct
Feb 5, 2025	SPRO Spero Therapeutics, Inc.	Sale(S)	42,786	$0.78	$33,373	Direct
Feb 5, 2025	SPRO Spero Therapeutics, Inc.	Sale(S)	106,408	$0.78	$82,998	Direct
Feb 3, 2025	SPRO Spero Therapeutics, Inc.	Award(A)	751,407	-	-	Direct

1-4 of 4 transactions

About Shukla Sath

Shukla Sath (SEC CIK 0001782817) files insider reports with the SEC as CEO & President of Spero Therapeutics, Inc. (SPRO).

Signal8 holds 1 ownership filing by Shukla Sath, a Form 4, filed on Feb 5, 2025. Those filings report 4 transactions, from Feb 3, 2025 to Feb 5, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Shukla Sath's filings is in CAMBRIDGE, MA.

Recent filings by Shukla Sath

Feb 5, 2025: Open-market sales of SPRO shares (3 lines, Form 4, code S).
Feb 3, 2025: Grant or award of SPRO shares (Form 4, code A).

Other insiders filing for Spero Therapeutics, Inc. (SPRO)

Zack Debra, Chief Medical Officer
Deshpande Milind, Director
Tregoning Kathleen, Director
Smith Cynthia, Director
VINK PATRICK V.J.J., Director
THOMAS FRANK E, Director

How to read Form 4 transaction codes